COVID-19 RCTs registered in ClinicalTrials.gov differ regarding dosing, route, or chemical form, have a non-random or non-blinded design, studied heterogeneous populations with individual variability [240], report selected endpoints, add other drugs (hydroxychloroquine, azithromycin, vitamin C, D, resveratrol ivermectin, doxycycline, tocilizumab, dexamethasone, famotidine nitazoxanide, ribavirin, darunavir, ritonavir, lactoferrin, nitazoxanide, quercetin, or bromelain, oral methylene blue solution, inhaled phenformin, and selenium micronutrients) [241,242], have not yet been completed. The gene discussed is LTF; the disease is COVID-19.